The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 09, 2005
Filed:
Jan. 14, 2000
Min Teng, San Diego, CA (US);
Larry Kenneth Truesdale, San Diego, CA (US);
Dilip Bhumralkar, San Diego, CA (US);
Dan Kiel, San Diego, CA (US);
Michael D. Johnson, San Diego, CA (US);
Christine Thomas, San Diego, CA (US);
Anker Steen Jorgensen, Copenhagen, DK;
Peter Madsen, Bagsvaerd, DK;
Preben Houlberg Olesen, Copenhagen, DK;
Liselotte Bjerre Knudsen, Valby, DK;
Ingrid Vivika Petterson, Frederiksberg, DK;
Johannes Cornelis DE Jong, Bagsvaerd, DK;
Carsten Behrens, Copenhagen, DK;
Janos Tibor Kodra, Copenhagen, DK;
Jesper Lau, Farum, DK;
Min Teng, San Diego, CA (US);
Larry Kenneth Truesdale, San Diego, CA (US);
Dilip Bhumralkar, San Diego, CA (US);
Dan Kiel, San Diego, CA (US);
Michael D. Johnson, San Diego, CA (US);
Christine Thomas, San Diego, CA (US);
Anker Steen Jorgensen, Copenhagen, DK;
Peter Madsen, Bagsvaerd, DK;
Preben Houlberg Olesen, Copenhagen, DK;
Liselotte Bjerre Knudsen, Valby, DK;
Ingrid Vivika Petterson, Frederiksberg, DK;
Johannes Cornelis de Jong, Bagsvaerd, DK;
Carsten Behrens, Copenhagen, DK;
Janos Tibor Kodra, Copenhagen, DK;
Jesper Lau, Farum, DK;
Novo Nordisk A/S, Bagsvaerd, DK;
Abstract
Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.